Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
Carlos Doti, VP US Medical Affairs Oncology at AstraZeneca, shared on LinkedIn:
”As I reflect on another ASH, I’m reminded why this meeting is such a powerful close to the year – where science, collaboration and patient experiences come together to shape the future of hematology.
This year, I participated in two meaningful AstraZeneca events:
Moderating our annual Patient Advocacy Exchange panel with advocacy leaders focused on shared decision-making and patient navigation, discussing how to break down barriers and promote equitable access to care.
Hosting our first-ever AZHemeTalks – a live, pop-up series – at our booth, where I spoke with a clinical trial patient and her doctor about how treatment choices impact daily life.
The video here shows how we brought this activation to life through 4 expert panels focused on the treatment landscape in leukemia, lymphomas and multiple myeloma.”
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 02:46Arman Qamar: Drug-Coated Balloons in Coronary Bifurcation PCI
-
Oct 4, 2026, 01:13Francesc Formiga: Updated Evidence on LAA Closure Versus Oral Anticoagulation in AF
-
Oct 4, 2026, 01:11Alicja Urbaniak: Targeting CD148 to Develop New Antithrombotic Therapies
-
Oct 4, 2026, 01:03Susan Mou: Presenting Long-Term Clinical Outcomes in SCD and TDT
-
Oct 4, 2026, 01:00Mark Johnson: Elevating Patient and Warrior Voices During Sickle Cell Awareness Month
-
Oct 4, 2026, 00:55Pier Maria Fornasari: Possible New Target for SCD and Beta Thalassemia Treatment
-
Oct 4, 2026, 00:48Sthanu Subramanian: Mechanisms, Clinical Phenotypes, Imaging, and Treatment of CVT
-
Oct 4, 2026, 00:33Ashish Pemawat: Can We Protect the Brain while We Restore Blood Flow?
-
Oct 4, 2026, 00:32Marta Nowakowska-Kotas: Could a Small Rise in Creatinine after Thrombectomy in Stroke Patients Be an Early Warning Sign?